The European Union said on Friday that it will ease its restrictions on exporting COVID-19 vaccines.
The Commission, the EU's executive arm, said that as of January it will no longer require vaccine producers to request special authorisation to export outside the 27-nation bloc.
Earlier this year when vaccines were still in short supply, the EU introduced a mechanism to keep some of the jabs it secured from AstraZeneca, the Anglo-Swedish drug company, from being diverted elsewhere.
The export control system, aimed at making sure large drug companies would respect their contracts, was used by the EU in March, when a shipment of more than a quarter million AstraZeneca vaccines destined for Australia was blocked from leaving.
When the dispute with AstraZeneca broke, the EU was lagging well behind the United States and other countries in COVID-19 vaccinations. According to Stella Kyriakides, the Commissioner for Health, the bloc has now vaccinated over 65% of the total EU population of some 450 million inhabitants.
The EU and AstraZeneca said in September that they reached a deal to end their legal battle over the slow pace of deliveries of the company's COVID-19 vaccines.
EU commission spokeswoman Dana Spinant said the transparency of exports will be ensured by a new monitoring mechanism that will provide the commission with companies' vaccine export data.
Spinant noted that the EU is the biggest global provider of COVID-19 vaccines, with over 1.3 billion doses exported to more than 150 countries.
Amid a new significant uptick in infections in the EU, European Commission President Ursula von der Leyen said vaccinations need to be stepped up further.
"We need to convince more people to get vaccinated," she said. "The good news is that we have enough vaccine doses. By the end of this week, Europe will have delivered 1 billion doses to our member states.
(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
)